Introduction

Microbial infections (bacterial pyoderma and *Malassezia* dermatitis) are one of the most frequent diseases in canine dermatology [1]. Their treatment usually necessitates the use of systemic antimicrobial drugs such as respectively antibiotics and antifungals [2]. However, antimicrobial resistance has become a recent issue in veterinary dermatology and it is therefore currently recommended, when possible, to avoid the use of such products [2-4]. The topical application of antiseptic products, initially considered only as a valuable adjunctive therapy, has been recently demonstrated in preliminary studies to be of benefit to either prevent the use or reduce the total dose of antibiotics for bacterial pyoderma [5-9]. For *Malassezia* dermatitis, it has also been demonstrated for localized cases that topical application of antifungal agents was as effective as the oral administration of ketoconazole both for reducing clinical signs and yeasts counts [10]. However, even if potentially effective as demonstrated in clinical trials in referral centres, it is not known if this approach is considered as efficacious and satisfactory by owners and veterinarians in general practice. The aim of this opened non controlled study was to evaluate the value of a novel spray, containing essential oils and essential fatty acids from plant extracts with antimicrobial properties in the treatment of staphylococcal and/or *Malassezia pachydermatis* infections in dogs and to assess the evaluation of this products by owners and veterinarians.

Material and Methods

This was an opened multicentre study conducted in 22 veterinary clinics in various countries (France 1, Germany 5, Japan 1, Taiwan 1, South Africa 2, USA 1, China 8, Malaysia 1, Spain 2). Private owned dogs suffering from an infectious dermatosis (either bacterial pyoderma and/or *Malassezia* dermatitis) were treated with a spray containing essential plants in an uncontrolled trial. Written owner consent was obtained before including the animals when needed by regulatory rules depending on the countries.
Dogs

Dogs of any age, breed and sex presented to a veterinarian with clinical signs compatible with either superficial bacterial pyoderma or Malassezia dermatitis were included in the study. Lesions consistent with bacterial pyoderma included papules, pustules, epidermal collarettes and/or crusts/cales. Lesions consistent with Malassezia dermatitis included erythema, greasy seborrhea and/or scaling. Cytological examination consistent with bacterial pyoderma included the presence of cocci phagocytosed by neutrophils on microscopical examination and cytological examination consistent with Malassezia dermatitis included the presence of numerous (at least 5) yeasts per field at high power (Gx100). Dogs suffering from deep pyodermas (presence of furuncles, erosions and/or ulcers) were excluded as they were unlikely to benefit from the use of the topical product alone. Dogs suffering from a parasitic skin disease (eg demodicosis, sarcoptic mange, flea infestation) were excluded by skin scrapings, flea combing and when needed a serological examination.

To be included, dogs should not have been treated in the past 7 days with any topical product and systemic antibiotics. The owners agreed to perform the treatment and to comply with the visits and signed an informed consent if needed by regulatory authorities.

Clinical Scoring

At inclusion, the Investigator collected a patient history and completed a standard physical and dermatological examination. The diagnosis of bacterial pyoderma and/or Malassezia dermatitis was performed and the lesions were scored depending on their extension and their severity. The extent was qualified as 0 (no lesion), 1 (one lesion), 2 (2 to 3 lesions) and 3 (more than 3 lesions). The severity was scored as 0 (absence), 1 (mild), 2 (moderate), 3 (rather severe) and 4 (severe). Veterinary and owner satisfactions were assessed as 0 (unsatisfied), 1 (moderately satisfied), 2 (satisfied) and 3 (very satisfied).

Treatment

Each dog was treated with the application of the tested product (Dermoscent® PYOclean® Spray, Laboratoire de Dermo-Cosmetique Animale, Castres, France) directly on the lesions twice daily. The continuation of use of an insecticidal therapy (product and dosage to be decided by the veterinarian) was needed to prevent a flea infestation during the trial period. Follow-up visits were scheduled after 10 and 21 days. At each visit a clinical and cytological evaluation was performed and the owners were asked about any side effect and about their satisfaction.

Data Analysis

Data were expressed as mean, standard deviation (SD) and range. For each clinical parameter and lesion score, the Wilcoxon signed-rank test was used to compare the scores of both groups at each visit.

Clinical efficacy was calculated as the percentage of change between each post-treatment and pre-treatment total scoring count using the formula: % Reduction = [1 – (PostTx value ÷ PreTx value)] x 100. Statistical significance was declared when P < 0.05. The primary software was GraphPad Prism version 5.00 for Windows (GraphPad Software, San Diego California USA).

Results

Study Population

22 veterinary clinics included 47 dogs from South Africa (2 clinics, 2 dogs), USA (1 clinic, 1 dog), Germany (5 clinics, 20 dogs), Japan (1 clinic, 3 dogs), France (1 clinic, 2 dogs), China (8 clinics, 8 dogs), Malaysia (1 clinic, 6 dogs), Taiwan (1 clinic, 3 dogs) and Spain (2 clinics, 2 dogs). 23 different breeds were represented, with French Bouledogues, Labrador retrievers Poodles and cross-breeds over represented (4 cases each). 23 females (12 intact and 11 neutered) and 24 males (16 intact and 8 neutered), aged from 8 months to 17 years (median 4.7 years), weighing from 1.8 to 53.6 kgs (median 17.5 kgs) were included.

Clinical Scores

All the dogs completed the study. At inclusion various lesions were present: erythema (19 cases), papules (14 cases) pustules (9 cases), epidermal collarettes (5 cases), scales/crusts (14 cases), greasy seborrhea (6 cases), alopecia (6 cases), hot spot (4 cases), oozing/erosions (9 cases), lichenification/hyperpigmentation (7 cases). Lesions were localized on the head and ears (19 cases), the feet (10 cases), the thorax/axillary area (13 cases), the abdominal/inguinal area (21 cases), the neck (5 cases) and/or the back (11 cases). At inclusion, extent score of the lesions was 2.062 (SD 0.8418) and this parameter decreased throughout the study period (less 22.55% after 10 days, p < 0.05%, Wilcoxon signed rank test; less 37.15% after 21 days, p < 0.001%, Wilcoxon signed rank test) (Figure 1). Severity scores also significantly decreased with time with an improvement of 41.90% after 10 days and 61.01% after 21 days (p < 0.01, Wilcoxon signed rank test) (Figure 2).

Owner and Veterinarian Appreciation

Owners were satisfied or very satisfied in 89% of the cases. Veterinarians were satisfied or very satisfied in 90% of the cases.

Side Effects

Only few side effects (burning sensation, pruritus, erythema) at the site of application were reported during the study, most of them being benign and spontaneously regressing after treatment withdrawal (5/47 dogs).

Discussion

The aim of our study was to confirm that the use of a non-antibiotic spray containing essential oils and essential fatty acids from plant extracts, demonstrated previously to have antimicrobial properties [5], was of interest in the management of bacterial pyoderma and/or Malassezia dermatitis in dogs in the field. Bacterial and Malassezia overgrowth are very common in general practice [1-4]. They are usually associated with an underlying disease, such as allergy. Beside the control of the primary disease, their treatment depends on the extent and severity of clinical signs and the possibility to use topical treatments [4]. Topical

http://scidoc.org/IJVHSR.php
treatment is not only an interesting adjunctive therapy but can avoid, in some cases, the use of systemic treatments notably antibiotics [3]. Due to the emergence of methicillin-resistant Staphylococcus pseudintermedius (MRSP) and other multi-drug resistant staphylococci in veterinary dermatology, the value of alternative options to antibiotics has been the scope of various studies and reviews, both in vivo and in vitro, but mainly using biocide products such as chlorhexidine [7-9]. The tested product, Dermoscent® PYOclean® spray is composed of N-acetylcysteine (NAC) associated with lavendin, manuka and hempseed oil. An oligosaccharidic prebiotic completes the formula. NAC is a molecule derived from the amino acid cysteine, commonly used as antioxidant and free-radical scavenging, because it increases cellular production of glutathione. It has also interesting properties in the dermatology field as the ability to prevent biofilm formation, treat microbial infections and restore skin integrity [11, 12]. Biofilm is a multicellular microbial community of one or more microorganisms extremely capable to self-reproduce on biological surfaces. It is a complex ecosystem that provides extra protection for the sessile bacteria cells inside the biofilm from external factors such as dessication, the host immune response and antimicrobials. Systemic antibiotics are often ineffective because of their slow and incomplete penetration into the deepest layers of biofilm [4]. The control of biofilm growth is therefore a really challenging target as biofilm formation may be involved in many chronic and relapsing infections, including skin infections. In vitro and in vivo studies have demonstrated that NAC is effective in inhibiting biofilm formation, disrupting preformed biofilms and reducing bacterial viability in biofilms [11]. Manuka oil, another component of the spray, can also interfere with biofilm formation [13], and has a synergistic action with NAC. NAC has shown antibacterial effects against a variety of Gram-negative and Gram-positive bacteria [12]. It has a synergistic activity with lavendin, manuka and hempseed oil, that have all demonstrated antibacterial activity, both in vitro and in vivo, notably against Gram-positive bacteria including some antibiotic-resistant strains [13-15]. These essential oils are also efficacious against yeasts [16, 17]. This is important because commonly used antiseptic products in dermatology have mainly activity against bacteria. The use of a product combining activity against bacteria and Malassezia is preferable. Finally, the spray may also be effective by improving skin integrity and skin barrier function. In effect, beside anti-inflammatory effect and promotion of wound healing [18] NAC can decrease transepidermal water loss and thus contribute to restore the skin barrier [19]. Hempseed oil is a rich and balanced source of omega-6 and omega-3 polyunsaturated fatty acids [20] and it is now well recognized that polyunsaturated fatty acids are of great importance for the integrity of skin barrier [21]. The restoration of skin barrier helps to improve the wellness of the animal by decreasing skin xerosis and itching and contribute to limit microbial proliferations as skin is less prone to secondary infections. These combined properties explain the good results.
obtained in this study, both on lesions directly linked to microbial infection such as papules, pustules and epidermal colllaretes and on lesions associated with chronic inflammation and altered skin barrier, such as scales, seborrhea or lichenification. The formulation as a spray permits to treat extensive area and is easy to use. The relatively low viscosity of the product makes it suitable for haired skin and its consistency permits great adherence to skin surface. These characteristics explain that close to 90% (89%) of owners are very satisfied of the spray. Despite the good results obtained here, with a statistically significant improvement of both extent and severity of lesions after treatment, there are some limits in our study, notably its opened, uncontrolled character and the inclusion of dogs with various clinical presentations. Therefore, these very encouraging results need to be confirmed with further controlled studies in the field.

Acknowledgements

This study was carried out with the support of Laboratoire de Dermo-Cosmétique Animale (LDCA), Castres, France. The authors would like to thank Drs C. Anel, M. Bitsch, R. Butler, A. Cabrero, C. Chen, S. Chen, G. Duplessis, I. Esclapez Vegara, H.S. Han, K. Hofmann, I. Holz, Y.S. Hsiao, S. Jia, O. Koorts, J. Lee, M. Nagata, J. Neethling, M. Pacheco Duran, K. Paton, F. Schäfer, F. Shi, Z. Shi, D. Spith, S. White, B. Wieklein, I. Winkler, J. Xu, BJ. Yin, C. Zandi, P. Zeng, L. Zhang and D. Zhu for their cases included in the study.

Conclusion

These results confirm that the use of a topical treatment with a spray containing antimicrobial and antibiofilm agents may be of interest for the management of microbial infections in dogs on a clinical daily basis.

References